Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > where is the great francine in all this

<< Previous

Bullboard Posts

Next >>

Comment by scoproon Jan 17, 2020 8:41pm

60 Views

Post# 30567689

RE:RE:RE:RE:RE:RE:RE:RE:RE:where is the great francine in all this

How did Vascepa's diet/statin protocol compare to Capre's? Shouldn't they legally be the same or very similar? Either cornstarch is king or it is not.

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery